endosergЭндокринная хирургияEndocrine Surgery2306-35132310-3965Типография «Печатных дел Мастер»10.14341/2306-3513-2008-1-29-39endoserg-4034Research ArticleСтатьиArticlesДиабетическая дистальная полинейропатияDiabeticheskaya distal'naya polineyropatiyaDemidovaI Yu-KhramilinV N-IgnatovaO Yu-20081503200821№1 (2008)2939Copyright © Demidova I.Y., Khramilin V.N., Ignatova O.Y., 20082008Demidova I.Y., Khramilin V.N., Ignatova O.Y.Demidova I.Y., Khramilin V.N., Ignatova O.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.surg-endojournals.ru/jour/article/view/4034

Нейропатия одно из самых частых хронических осложнений сахарного диабета (СД), выявляемое почти у 50 % пациентов [27, 50, 77, 166]. Клинические проявления широко варьируют и могут затрагивать разные специальности от дерматологии до подиатрии, от урологии до кардиологии. Диабетическая нейропатия (ДН) наличие симптомов и/или признаков дисфункции периферической нервной системы у лиц с СД при исключении других возможных причин [23]. Диагноз нейропатии не может быть установлен без предварительного и тщательного клинического обследования, при этом отсутствие симптомов не говорит об отсутствии нейропатии, поскольку часто встречается бессимптомная нейропатия. Важность исключения других причин развития ДН была подчеркнута в Рочестерском исследовании, в котором примерно 10% больных СД имели нейропатии другой, не связанной с СД, этиологии [50]. Диагноз ДН правомочен при наличии минимум двух отклонений (наличие симптомов, нарушение чувствительности, нарушение нервной проводимости, изменения количественных сенсорных или автономных тестов) [54].

ReferencesAbad F, Diaz-Gomez NM, Rodriguez I, Perez R, Delgado JA: Subclinical pain and thermal sensory dysfunction in children and adolescents with type 1 diabetes mellitus. Diabet Med 19:827-831, 2002Abad F, Diaz-Gomez NM, Rodriguez I, Perez R, Delgado JA: Subclinical pain and thermal sensory dysfunction in children and adolescents with type 1 diabetes mellitus. Diabet Med 19:827-831, 2002Abbott CA, Carrington AL, Ashe H, et al. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med 19: 377-384, 2002Abbott CA, Carrington AL, Ashe H, et al. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med 19: 377-384, 2002Abbott CA, Vileikyte L, Williamson S, Carrington AL, Boulton AJM: Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care 7:1071-1075, 1998Abbott CA, Vileikyte L, Williamson S, Carrington AL, Boulton AJM: Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care 7:1071-1075, 1998Airey M, Bennett C, Nicolucci A, Williams R: Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy. Cochrane Database Syst Rev 2:CD002182, 2000Airey M, Bennett C, Nicolucci A, Williams R: Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy. Cochrane Database Syst Rev 2:CD002182, 2000Akbari CM, Gibbons GW, Habershaw GM, et al. The effect of arterial reconstruction on the natural history of diabetic neuropathy. Arch-Surg 132:148-152,1997Akbari CM, Gibbons GW, Habershaw GM, et al. The effect of arterial reconstruction on the natural history of diabetic neuropathy. Arch-Surg 132:148-152,1997Amano S, Kaji Y, Oshika T, Oka T,et al. Advanced glycation end products in human optic nerve head. Br J Ophthalmol 85:52-55, 2001Amano S, Kaji Y, Oshika T, Oka T,et al. Advanced glycation end products in human optic nerve head. Br J Ophthalmol 85:52-55, 2001American Diabetes Association, American Academy of Neurology: Report and recommendations of the San Antonio Conference on Diabetic Neuropathy (Consensus Statement). Diabetes Care 11:592-597, 1988American Diabetes Association, American Academy of Neurology: Report and recommendations of the San Antonio Conference on Diabetic Neuropathy (Consensus Statement). Diabetes Care 11:592-597, 1988Ametov A. S., Barinov A., Dyck PJ. et al. The Sensory Symptoms of Diabetic Polyneuropathy Are Improved With a -Lipoic Acid (The SYDNEY Trial). Diabetes Care 26:770-776, 2003.Ametov A. S., Barinov A., Dyck PJ. et al. The Sensory Symptoms of Diabetic Polyneuropathy Are Improved With a -Lipoic Acid (The SYDNEY Trial). Diabetes Care 26:770-776, 2003.Anand P, Terenghi G, Warner G et al. The role of endogenous nerve growth factor in human diabetic neuropathy. Nat Med 2:703-707, 1996Anand P, Terenghi G, Warner G et al. The role of endogenous nerve growth factor in human diabetic neuropathy. Nat Med 2:703-707, 1996Apfel SC, Kessler JA, Adornato BT et al. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy: NGF Study Group. Neurology 51:695702, 1998Apfel SC, Kessler JA, Adornato BT et al. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy: NGF Study Group. Neurology 51:695702, 1998Apfel SC, Schwartz S, Adornato BT et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. JAMA 284: 2215-2221, 2000Apfel SC, Schwartz S, Adornato BT et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. JAMA 284: 2215-2221, 2000Archer aG, Watkins PJ, Thomas PK, Sharma AK, Payan J: The natural history of acute painful neuropathy is diabetes. J Neurol Neurosurg Psych 48:491^99, 1983Archer aG, Watkins PJ, Thomas PK, Sharma AK, Payan J: The natural history of acute painful neuropathy is diabetes. J Neurol Neurosurg Psych 48:491^99, 1983Armstrong DG, Lavery LA, Vela SA, Quebedeaux TC, Fleischli JG: Choosing a practical screening instrument to identify patients at risk of diabetic foot ulceration. Arch Int Med 153:289-292, 1998Armstrong DG, Lavery LA, Vela SA, Quebedeaux TC, Fleischli JG: Choosing a practical screening instrument to identify patients at risk of diabetic foot ulceration. Arch Int Med 153:289-292, 1998Azad N, Emanuele NV, Abraira C, Henderson WG, et al. The effects of intensive glycemic control on neuropathy in the VA Cooperative Study on Type II Diabetes Mellitus (VA CSDM). J Diabetes Compl 13:307-313, 1999Azad N, Emanuele NV, Abraira C, Henderson WG, et al. The effects of intensive glycemic control on neuropathy in the VA Cooperative Study on Type II Diabetes Mellitus (VA CSDM). J Diabetes Compl 13:307-313, 1999Backes JM, Howard PA: Association of HMG-CoA reductase inhibitors with neuropathy. Ann Pharmacother 37:274278, 2003Backes JM, Howard PA: Association of HMG-CoA reductase inhibitors with neuropathy. Ann Pharmacother 37:274278, 2003Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. JAMA. 1998;280:1831-1836.Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. JAMA. 1998;280:1831-1836.Barbano RL, Herrmann DN, Hart-Gouleau S et al. Effectiveness, tolerability and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol 2004; 61:914-8Barbano RL, Herrmann DN, Hart-Gouleau S et al. Effectiveness, tolerability and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol 2004; 61:914-8Biesbroeck R, Bril V, Hollander P et al. A double-blind comparison of topical capsaicin and oral amitriptyline in painful diabetic neuropathy. Adv Ther 12:111-120,1995Biesbroeck R, Bril V, Hollander P et al. A double-blind comparison of topical capsaicin and oral amitriptyline in painful diabetic neuropathy. Adv Ther 12:111-120,1995Biewega, Haenen, Bast. The role of lipoic acide in the treatment of diabetic polyneuripathy. Drug Met. Rew. 29(4), 1997. pp. 1025-1054Biewega, Haenen, Bast. The role of lipoic acide in the treatment of diabetic polyneuripathy. Drug Met. Rew. 29(4), 1997. pp. 1025-1054Booth J, Young MJ: Differences in the performance of commercially available monofilaments. Diabetes Care 23:984-988, 2000Booth J, Young MJ: Differences in the performance of commercially available monofilaments. Diabetes Care 23:984-988, 2000Boulton A. J.M., Malik R. A., Arezzo J. C., Sosenco J. M. Diabetic Somatic Neuropathies. Diab. Care, Vol. 27, N 6, Jun 2004, p:1458-1486.Boulton A. J.M., Malik R. A., Arezzo J. C., Sosenco J. M. Diabetic Somatic Neuropathies. Diab. Care, Vol. 27, N 6, Jun 2004, p:1458-1486.Boulton AJM, Drury J, Clarke B, Ward JD: Continuous subcutaneous insulin infusion in the management of painful diabetic neuropathy. Diabetes Care 5: 386-390, 1982Boulton AJM, Drury J, Clarke B, Ward JD: Continuous subcutaneous insulin infusion in the management of painful diabetic neuropathy. Diabetes Care 5: 386-390, 1982Boulton AJM, Gries FA, Jervell JA: Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. Diabet Med 15:508-514, 1998Boulton AJM, Gries FA, Jervell JA: Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. Diabet Med 15:508-514, 1998Boulton AJM, Kubrusly DB, Bowker JH, Skyler JS, Sosenko JM: Impaired vibratory perception and diabetic foot ulceration. Diabet Med 3:335-337, 1986Boulton AJM, Kubrusly DB, Bowker JH, Skyler JS, Sosenko JM: Impaired vibratory perception and diabetic foot ulceration. Diabet Med 3:335-337, 1986Boulton AJM, Malik RA: Diabetic neuropathy. Med Clin N Am 82:909-929,1998Boulton AJM, Malik RA: Diabetic neuropathy. Med Clin N Am 82:909-929,1998Bril V: Electrophysiologic testing. In Textbook of Diabetic Neuropathy. Gries FA, Cameron NE, Low PA, Ziegler D, Eds. Stuttgart, Thieme, 2003, p. 177-184Bril V: Electrophysiologic testing. In Textbook of Diabetic Neuropathy. Gries FA, Cameron NE, Low PA, Ziegler D, Eds. Stuttgart, Thieme, 2003, p. 177-184Cabezas-Cerrato J: The prevalence of diabetic neuropathy in Spain: a study in primary care and hospital clinic groups. Diabetologia 41:1263-1269, 1998Cabezas-Cerrato J: The prevalence of diabetic neuropathy in Spain: a study in primary care and hospital clinic groups. Diabetologia 41:1263-1269, 1998Carmeliet P, Storkebaum E: Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders. Semin Cell Dev Biol 13:39-53, 2002Carmeliet P, Storkebaum E: Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders. Semin Cell Dev Biol 13:39-53, 2002Carrington AL, Abbott CA, Shaw JE, Vileikyte L, Van Schie CHM, Boulton AJM: Can motor nerve conduction velocity predict foot problems in diabetic neuropathy over a 6-year outcome period? Diabetes Care 25:2010-2015, 2002Carrington AL, Abbott CA, Shaw JE, Vileikyte L, Van Schie CHM, Boulton AJM: Can motor nerve conduction velocity predict foot problems in diabetic neuropathy over a 6-year outcome period? Diabetes Care 25:2010-2015, 2002Catherine L. Martin et al. Neuropathy Among the Diabetes Control and Complications Trial Cohort 8 Years After Trial Completion. Diab. Care, Vol. 29, N.2, 2006; р: 340-344.Catherine L. Martin et al. Neuropathy Among the Diabetes Control and Complications Trial Cohort 8 Years After Trial Completion. Diab. Care, Vol. 29, N.2, 2006; р: 340-344.Chad DA, Aronin N, Lundstrom R, et al. Does capsaicin relieve the pain of diabetic neuropathy? Pain 42:387-388, 1990Chad DA, Aronin N, Lundstrom R, et al. Does capsaicin relieve the pain of diabetic neuropathy? Pain 42:387-388, 1990Coppini DV, Wellmer A, Weng C, Young PJ, Anand P, Sonksen PH: The natural history of diabetic peripheral neuropathy determined by a 12 year prospective study using vibration perception thresholds. J Clin Neurosci 8: 520-524, 2001Coppini DV, Wellmer A, Weng C, Young PJ, Anand P, Sonksen PH: The natural history of diabetic peripheral neuropathy determined by a 12 year prospective study using vibration perception thresholds. J Clin Neurosci 8: 520-524, 2001Cotter MA, Ekberg K, Wahren J, Cameron NE: Effects of proinsulin C-peptide in experimental diabetic neuropathy: vascular actions and modulation by nitric oxide synthase inhibition. Diabetes 52:1812-1817, 2003Cotter MA, Ekberg K, Wahren J, Cameron NE: Effects of proinsulin C-peptide in experimental diabetic neuropathy: vascular actions and modulation by nitric oxide synthase inhibition. Diabetes 52:1812-1817, 2003Dahlin LB, Erikson KF, Sundkvist G: Persistent postoperative complaints after whole nerve sural nerve giopsies in diabetic and non-diabetic subjects. Diabet Med 14:353-356, 1997Dahlin LB, Erikson KF, Sundkvist G: Persistent postoperative complaints after whole nerve sural nerve giopsies in diabetic and non-diabetic subjects. Diabet Med 14:353-356, 1997Davies M., Brophy S., Williams R., Taylor A. The Prevalence, Severity, and Impact of Painful Diabetic Peripheral Neuropathy in Type 2 Diabetes. Diabetes Care 29:1518-1522, 2006.Davies M., Brophy S., Williams R., Taylor A. The Prevalence, Severity, and Impact of Painful Diabetic Peripheral Neuropathy in Type 2 Diabetes. Diabetes Care 29:1518-1522, 2006.Davis EA, Walsh P, Jones TW, Byrne GC: The use of biosthesiometry to detect neuropathy in children and adolescents with IDDM. Diabetes Care 20:14481453, 1997Davis EA, Walsh P, Jones TW, Byrne GC: The use of biosthesiometry to detect neuropathy in children and adolescents with IDDM. Diabetes Care 20:14481453, 1997Davis JL, Lewis SB, Gerich JE, Kaplan RA, Schultz TA,Wallin JD: Peripheral diabetic neuropathy treated with amitriptyline and fluphenazine. JAMA 238:2291-2292, 1977Davis JL, Lewis SB, Gerich JE, Kaplan RA, Schultz TA,Wallin JD: Peripheral diabetic neuropathy treated with amitriptyline and fluphenazine. JAMA 238:2291-2292, 1977Davis JL, Smith RL: Painful peripheral diabetic neuropathy treated with venlafaxine HCl extended release capsules. Diabetes Care22:1909-1910, 1999Davis JL, Smith RL: Painful peripheral diabetic neuropathy treated with venlafaxine HCl extended release capsules. Diabetes Care22:1909-1910, 1999

The authors declare that there are no conflicts of interest present.